Biotherapeutics Cell Line Development Market Will Enter Robust Revenue Ramp Reaching US $41 Mn by the End of 2022
Over the past few years, the demand for biotherapeutics has witnessed a significant rise, thanks to the increasing prevalence of chronic diseases such as diabetes, rheumatoid arthritis, cancer, and multiple sclerosis. This growth in the demand for biotherapeutics, together with the imminent launch of several biopharmaceutical drugs, has created a substantial demand for cell line development.
View full press release